The Secretary shall establish guidelines for the co–prescribing of opioid overdose reversal drugs that are applicable to all licensed health care providers in the State who are authorized by law to prescribe a monitored prescription drug, as defined in § 21–2A–01 of this article. The guidelines established under subsection (a) of this section shall address the co–prescribing of opioid overdose reversal drugs for patients who are: At an elevated risk of overdose; and Receiving opioid therapy for chronic pain; Receiving a prescription for benzodiazepines; or Being treated for opioid use disorders.